Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.50 |
| ▸ | SCD | O00767 | 1/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846972 | 0.78 | ALDH1A1 (0.51) | KMT2ASMN1; SMN2MEN1USP2TSHR | |
| SCHEMBL1586651 | 0.77 | MAPT (0.48) | MAPTKMT2ASMN1; SMN2LMNAMEN1 | |
| SCHEMBL13640120 | 0.75 | MAPT (0.45) | MAPTKMT2ASMN1; SMN2LMNAMEN1 | |
| SCHEMBL12301497 | 0.75 | MAPT (0.46) | MAPTKMT2ASMN1; SMN2LMNAMEN1 | |
| SCHEMBL12010945 | 0.72 | MAPT (0.59) | MAPTKMT2ASMN1; SMN2LMNAMEN1 | |
| Ensulizole SCHEMBL38724 | 0.71 | HDAC6 (1.00) | MAPTKMT2ASMN1; SMN2MEN1GAA | |
| Ensulizole SCHEMBL7751558 | 0.71 | HDAC6 (1.00) | MAPTKMT2ASMN1; SMN2MEN1GAA | |
| SCHEMBL2839555 | 0.70 | PKM (0.52) | MAPTLMNATP53POLB | |
| Ensulizole SCHEMBL1276071 | 0.70 | HDAC6 (0.97) | MAPTKMT2ASMN1; SMN2MEN1GAA | |
| Ensulizole SCHEMBL17351654 | 0.70 | HDAC6 (0.97) | MAPTKMT2ASMN1; SMN2MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2444120-B1 | Spirocyclic amiloride analogues as ENac blockers | NOVARTIS AG (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-9643983-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2017-05-09 | — | — | US | disclosed |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-9139586-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2015-09-22 | — | — | US | disclosed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| EP-2813227-A1 | Compositions for treatment of cystic fibrosis and other chronic diseases | Vertex Pharmaceuticals Incorporated (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140171421-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140121208-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-01 | — | — | US | disclosed |
| US-8697687-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20130012500-A1 | ORGANIC COMPOUNDS | BHALAY GURDIP (GB) | 2013-01-10 | — | — | US | disclosed |
| EP-2520574-A1 | Amiloride analogues substituted on the cyclic guanidine moiety as ENaC blockers for treating respiratory diseases | Novartis AG (CH) | 2012-11-07 | — | — | EP | disclosed |
| EP-2490687-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2231280-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
| WO-2009074575-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012500-A1 | ORGANIC COMPOUNDS | OR10J3, REN, CACNA1E | MAPT 2151/4885KMT2A 4325/4885SMN1; SMN2 1712/4885 |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | MAPT 4731/4885KMT2A 4359/4885SMN1; SMN2 3332/4885 |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | MAPT 3437/4885KMT2A 2584/4885SMN1; SMN2 812/4885 |
| US-20140121208-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | MAPT 4731/4885KMT2A 4359/4885SMN1; SMN2 3332/4885 |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | MAPT 4731/4885KMT2A 4359/4885SMN1; SMN2 3332/4885 |
| US-20100130506-A1 | Organic Compounds | OR10J3, REN, CACNA1E | MAPT 2151/4885KMT2A 4325/4885SMN1; SMN2 1712/4885 |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | MAPT 4731/4885KMT2A 4359/4885SMN1; SMN2 3332/4885 |
| US-20140171421-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | MAPT 3437/4885KMT2A 2584/4885SMN1; SMN2 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.